Groningen, The Netherlands, 28 September 2010

Mucosis B.V. and PATH sign agreement to pursue Mimopath®-based oral diarrhea vaccines

--> Download the pdf in Dutch

--> Download the pdf in English

Dutch biotechnology company Mucosis B.V. announced today that it has entered into a collaboration agreement with the global health nonprofit organization PATH to pursue the use of the company’s Mimopath™ technology in oral vaccines to prevent and treat severe diarrhea.

Severe dehydrating diarrhea is the second leading cause of death in children in developing countries and frequently causes disease in travelers visiting those areas. Shigella and enterotoxigenic E. coli (ETEC) are the leading bacterial causes of diarrhea. Currently, no vaccines against those bacteria exist. PATH supports the development of Shigella and ETEC vaccines.

Because Mimopath™-based vaccines have the potential to raise a strong immune response in the gut after oral administration, PATH is supporting Mucosis to establish proof of concept in animals. PATH will cover the company’s research costs up to US$600,000. If proof of concept is generated, the collaboration may be expanded.

“We are very proud to collaborate with PATH in applying our technology to the vital task of finding new vaccines targeting the threat of Shigella and ETEC,” said Govert Schouten, CEO of Mucosis.

Mucosis already collaborates with PATH on intranasal pneumococcal vaccines based on Mimopath®. This program started in 2009.

For further information please contact:

Govert Schouten
CEO Mucosis
+31 (6) 55320948

About Mucosis
Mucosis B.V. is a Dutch biotechnology company that has developed a proprietary vaccine platform technology, Mimopath® , on which it develops mucosal vaccines with improved efficacy. Mucosis’s lead products are FluGEM®, a vaccine to prevent influenza, and PneuGEM®, a vaccine preventing diseases caused by pneumococcal bacteria. Mimopath™ -based vaccines can be administered needle-free in the nose and mouth, evoking a more natural immune response with a broader base of protection.

About Mimopath® technology
Mucosis’s Mimopath® technology is based on Lactococcus lactis, a safe bacterium commonly used in the food industry. Mucosis has developed a robust technique to formulate the L. lactis bacteria into non-living bacterium-like particles (BLPs) that can be loaded with antigens from viral, bacterial, parasitic or tumor origin. The antigen-covered BLPs form a vaccine that can be delivered into the nose or mouth, without the need for a needle. These vaccines raise protective immunity by activation of both the innate and the adaptive immune system.

About PATH
PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, PATH helps provide appropriate health technologies and vital strategies that change the way people think and act. PATH’s work improves global health and well-being. For more information, please visit

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >